Mutational mechanisms of EZH2 inactivation in myeloid neoplasms.

doi:10.1038/s41375-020-0816-y

Article

Mutational mechanisms of EZH2 inactivation in myeloid neoplasms.

Leukemia - 1 Dec 2020

Chase Andrew, Score Joannah, Lin Feng, Bryant Catherine, Waghorn Katherine, Yapp Sarah, Carreno-Tarragona Gonzalo, Aranaz Paula, Villasante Aranzazu, Ernst Thomas, Cross Nicholas C P

Abstract excerpt

EZH2, a component of the polycomb repressive complex 2, catalyses the trimethylation of histone H3 lysine 27, a chromatin mark associated with transcriptional repression. EZH2 loss-of-function mutations are seen in myeloid neoplasms and are associated with an adverse prognosis. Missense mutations...

Topics

Animals
Cell Line
Enhancer of Zeste Homolog 2 Protein
Histones
Humans
Lysine
Mice
Mutation
Myeloproliferative Disorders

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.